ĐÁNH GIÁ SỰ THAY ĐỔI CÁC DẤU ẤN HUYẾT THANH Ở BỆNH NHÂN VIÊM GAN VI RÚT B MẠN TÍNH ĐIỀU TRỊ BẰNG TENOFOVIR TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI TRUNG ƯƠNG

Abstract

Objective: Assessment of changes in serological indexes in chronic hepatitis B virus patients treating tenofovir. Subjects and methods: A descriptive study combines retrospective and prospective studies in patients over 18 years of age diagnosed as having a chronic infection with the hepatitis B virus. The patients were indicated for the treatment according to the Vietnamese Ministry of Health guidelines in 2019 for the diagnosis and treatment of the hepatitis B virus and continuously treated with TAF, TDF. Results and conclusions: The results showed that the majority of study patients were male, accounting for 63.1%. In the male group, the proportion of patients in all age groups was similar; otherwise, the proportion of patients in the group 31-40 and above 50 years old was dominated in females.Treatment results in the month of 12th showed that the percentage of HBV DNA load below the threshold in the HBeAg (+) patients treated with TAF was higher than in the TDF-treated group, 53.3% and 52%, respectively.The prevalence of seroconversion achieved in the group of patients with HBeAg (+) converted to HBeAg (-) but without Anti-HBe (+) after 6 months and 12 months of treatment were 14.5% and 32,7% respectively. This increases according to treatment time. In comparison between two treatment groups, the proportion was slightly higher in the TAF-treated group than in the TDF-treated group, 16.7% versus 12% at month of treatment, respectively at 6^th month of treatment and 36.7% compared with 28.0% at the 12th month of treatment.  The difference was statistically.